Endocrine Carcinoma — Trials

Endocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 574
Recruiting: 291
Ph III recruiting: 33
Growth YoY: +1.5%
Industry share: 34%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (236)

clinicaltrialsPublishedShowing 101–150 of 906 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02595424	Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas	active not recruiting	Phase 2	67	ECOG-ACRIN Cancer Research GroupNETWORK	1	Jul 27, 2026	clinicaltrials
NCT05616624	ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers	terminated	Phase 1 / Phase 2	31	Washington University School of MedicineOTHER